Baseline [123I]FP-CIT SPECT (DaTSCAN) severity correlates with medication use at 3 years in Parkinson's disease

Acta Neurologica Scandinavica

Volumn 129, Issue 3, 2014, Pages 204-208

  Nissen, T ^a   Malek, N ^b   Grosset, K A ^b   Newman, E J ^b   Patterson, J ^b   Hadley, D ^b   Grosset, D G ^b  

^a Klinikum Bremerhaven Reinkenheide   (Germany)

^b SOUTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Parkinson's disease; Parkinsonism; Pharmacotherapy; Single photon emission computed tomography (SPECT); Striatonigral degeneration

Indexed keywords

ANTIPARKINSON AGENT; DOPAMINE TRANSPORTER; IODINE 123; LEVODOPA;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PARKINSON DISEASE; PUTAMEN; RANDOMIZED CONTROLLED TRIAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

PARKINSON'S DISEASE; PARKINSONISM; PHARMACOTHERAPY; SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT); STRIATONIGRAL DEGENERATION;

AGED; ANTIPARKINSON AGENTS; FEMALE; HUMANS; LEVODOPA; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PARKINSON DISEASE; PUTAMEN; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 84893130438     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/ane.12178     Document Type: Article

References (20)

1. Scherfler C, Schwarz J, Antonini A et al. Role of DAT-SPECT in the diagnostic work up of Parkinsonism. Mov Disord 2007;22:1229-38.
2. Zijlmans J. The role of imaging in the diagnosis of vascular parkinsonism. Neuroimaging Clin N Am 2010;20:69-76.
3. Contrafatto D, Mostile G, Nicoletti A et al. [(123)I]FP-CIT-SPECT asymmetry index to differentiate Parkinson's disease from vascular parkinsonism. Acta Neurol Scand 2012;126:12-6.
4. 123I]-FP-CIT SPECT striatal uptake. Mov Disord 2000;15:692-8.
5. 123I]b-CIT striatal uptake correlated with symptom severity in Parkinson's disease. Ann Neurol 1995;38:589-98.
6. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002;287:1653-61.
7. Whone A, Watts R, Stoessl A et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET Study. Ann Neurol 2003;54:93-101.
8. Kägi G, Bhatia KE, Tolosa E. The role of DAT-SPECT in movement disorders. J Neurol Neurosurg Psychiatry 2010;81:5-12.
9. Ravina B, Marek K, Eberly S et al. Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease. Mov Disord 2012;27:1392-7.
10. 123I] FP-CIT SPECT study in vascular parkinsonism and Parkinson's disease. Mov Disord 2007;22:1278-85.
11. 123I]FP-CIT SPECT interpretation for evaluation of parkinsonism by visual rating of parametric distribution volume ratio images. Q J Nucl Med Mol Imaging 2011;55:301-9.
12. 123I]-FP-CIT SPECT imaging. Mov Disord 2000;15:503-10.
13. Matsui T, Hirano A. An atlas of the human brain for computed tomography. Stuttgart: Gustau Fister Verlag, 1978.
14. Parkin S, Gregory R, Scott R et al. Unilateral and bilateral pallidotomy for idiopathic Parkinson's disease: a case series of 115 patients. Mov Disord 2002;17:682-92.
15. Ottaviani S, Tinazzi M, Pasquin I et al. Comparative analysis of visual and semi-quantitative assessment of striatal [123I]FP-CIT-SPET binding in Parkinson's disease. Neurol Sci 2006;27:397-401.
16. Benamer HT, Patterson J, Wyper DJ, Hadley DM, Macphee GJ, Grosset DG. Correlation of Parkinson's disease severity and duration with 123I-FP-CIT SPECT striatal uptake. Mov Disord 2000;15:692-8.
17. Ahlskog JE. Slowing Parkinson's disease progression: recent dopamine agonist trials. Neurology 2003;60:381-9.
18. Ravina B, Eidelberg D, Ahlskog JE, Albin RL, Brooks DJ et al. The role of radiotracer imaging in Parkinson disease. Neurology 2005;64:208-15.
19. Schillaci O, Pierantozzi M, Fillipi L et al. The effect of levodopa therapy on dopamine transporter SPECT imaging with (123)I-FP-CIT in patients with Parkinson's disease. Eur J Nucl Med Mol Imaging 2005;32:1452-6.
20. Foltynie T, Brayne C, Barker RA. The heterogeneity of idiopathic Parkinson's disease. J Neurol 2002;249:138-45.